Pre-filled Entyvio pen approved for more US patients

19 April 2024

Japanese pharma giant Takeda (TYO: 4502) has picked up a new approval for subcutaneous Entyvio (vedolizumab), for maintenance therapy of severely active Crohn’s disease.

The nod, based on data from the VISIBLE 2 study, covers use of the med for adults after induction therapy with intravenous Entyvio.

The US Food and Drug Administration has already approved the subcutaneous form of the biologic, in September 2023, for maintenance therapy in ulcerative colitis. The product is sold in the USA as a single-dose prefilled pen.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK